Trial · NCT00073307
Participant flow24
How many started, completed or left each group, period by period.
1 to 20 of 24
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Double-Blind (DB, as of ~31May2005) | STARTED | Sorafenib (Nexavar, BAY43-9006) | 451 | |
| Double-Blind (DB, as of ~31May2005) | STARTED | Placebo | 452 | |
| Double-Blind (DB, as of ~31May2005) | STARTED | Placebo Randomized, Switch to Sorafenib; Sorafenib Period Only | 0 | |
| Double-Blind (DB, as of ~31May2005) | Participants Received Treatment | Sorafenib (Nexavar, BAY43-9006) | 451 | |
| Double-Blind (DB, as of ~31May2005) | Participants Received Treatment | Placebo | 451 | |
| Double-Blind (DB, as of ~31May2005) | Participants Received Treatment | Placebo Randomized, Switch to Sorafenib; Sorafenib Period Only | 0 | |
| Double-Blind (DB, as of ~31May2005) | COMPLETED | Sorafenib (Nexavar, BAY43-9006) | 254 | |
| Double-Blind (DB, as of ~31May2005) | COMPLETED | Placebo | 299 | |
| Double-Blind (DB, as of ~31May2005) | COMPLETED | Placebo Randomized, Switch to Sorafenib; Sorafenib Period Only | 0 | |
| Double-Blind (DB, as of ~31May2005) | NOT COMPLETED | Sorafenib (Nexavar, BAY43-9006) | 197 | |
| Double-Blind (DB, as of ~31May2005) | NOT COMPLETED | Placebo | 153 | |
| Double-Blind (DB, as of ~31May2005) | NOT COMPLETED | Placebo Randomized, Switch to Sorafenib; Sorafenib Period Only | 0 | |
| Open Label-Sorafenib Only [30Jun2008] | STARTED | Sorafenib (Nexavar, BAY43-9006) | 254 | |
| Open Label-Sorafenib Only [30Jun2008] | STARTED | Placebo | 0 | |
| Open Label-Sorafenib Only [30Jun2008] | STARTED | Placebo Randomized, Switch to Sorafenib; Sorafenib Period Only | 299 | |
| Open Label-Sorafenib Only [30Jun2008] | Entered OL With Sorafenib Only Phase | Sorafenib (Nexavar, BAY43-9006) | 219 | |
| Open Label-Sorafenib Only [30Jun2008] | Entered OL With Sorafenib Only Phase | Placebo | 0 | |
| Open Label-Sorafenib Only [30Jun2008] | Entered OL With Sorafenib Only Phase | Placebo Randomized, Switch to Sorafenib; Sorafenib Period Only | 216 | |
| Open Label-Sorafenib Only [30Jun2008] | COMPLETED | Sorafenib (Nexavar, BAY43-9006) | 120 | |
| Open Label-Sorafenib Only [30Jun2008] | COMPLETED | Placebo | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00073307/flow